ALECR Eurofins-Cerep SA
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company also provides research services, including compound management, and high-throughout screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and is based in Celle-Lévescault, France. Eurofins-Cerep SA is a subsidiary of Eurofins Discovery Services LUX Holding SARL.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Eurofins-Cerep (EPA: ALECR)
›
Eurofins-Cerep (EPA: ALECR) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector.
The shares were at 15000.00 EUR on 18 November 2026, down 6.8% over 52 weeks. Its 52-week range is 15000.00 EUR to 18600.00 EUR, and it trades at the bottom of that range.
At a market capitalisation of 75.66M EUR, it trades at 9.7 times trailing earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 73% for ALECR.
Eurofins-Cerep reports return on equity of 6.3%, an operating margin of 8.2% and revenue up 10.9% year over year.
It holds more cash than debt, a net cash position of 21.03M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.